However, recent data from a first phase III trial in patients with unresectable stage III or IV melanoma receiving epacadostat plus pembrolizumab or placebo plus pembrolizumab showed no clinical improvement for the addition of the IDO inhibitor to pembrolizumab (19). Here, IDO1 is linked to melanoma.